The Hike Came
Off the Table.
Week of August 17 — LYB · DBVT · GWRE
July CPI landed right on consensus and September hold odds jumped to ~62–64%[cite: 5]. Into the relief: a deep-value cyclical, a binary biotech catalyst, and a quality compounder that has already run[cite: 5].
July CPI landed on target, and September cooled
The July CPI arrived August 12 almost exactly where economists expected: headline +0.1% on the month, 3.4% annual, core +0.2% and 2.5% annual[cite: 5]. Both annual readings eased a tenth from June, and all four matched the Dow Jones consensus — a second consecutive benign print[cite: 5].
Odds of a September hike fell to roughly 38%, with a hold now ~62–64%, up from about 52% a day earlier[cite: 5]. Energy fell another 1.5% after June's 5.7% drop (though still +14.7% year-over-year), and — less comfortably — July payrolls showed the economy shedding 23,000 jobs[cite: 5]. A weak labor market makes tightening far harder to justify[cite: 5].
The hawkish pressure that dominated our last two issues has eased — but this is not an all-clear[cite: 5]. Inflation is still well above the 2% target, shelter accounted for about two-thirds of the headline increase, and July PCE, August payrolls and August CPI all land before the September 15–16 FOMC[cite: 5].
So the list spans three different kinds of trade, not three versions of one: a deep-value industrial cyclical at a possible cycle peak, a pre-revenue biotech facing a binary regulatory event, and a quality compounder we flagged two weeks ago that has already moved[cite: 5]. None reports during the coming week.[cite: 5]
The deep-value cyclical
LYB carries the highest frequency here at 87.5% and a solid 7.13 profit factor, though its 68.5% annualized return is the most modest of the three[cite: 5]. A dependable, unspectacular profile — which suits the name[cite: 5].
LyondellBasell is one of the world's largest chemical and plastics manufacturers[cite: 5]. The July 31 quarter was spectacular: adjusted EPS of $4.30 against a $3.42 consensus, EBITDA of $2.1B — more than triple Q1 — at a 23% margin on record polyethylene price increases, with free cash flow growth up 178%[cite: 5]. Analysts now model ~$8.73 non-GAAP EPS for 2026, up over 400% from $1.70[cite: 5].
Those records exist because the Middle East war steepened the global cost curve for petrochemicals — management said so directly — handing LYB's cost-advantaged US production a windfall[cite: 5]. War premiums fade[cite: 5]. JPMorgan upgraded to Overweight at $80 while noting plainly that Lyondell is earning above its normalized earnings level[cite: 5]. The street is split hard: Goldman $62 (Sell) and BofA $48, versus Morgan Stanley $72 and JPMorgan $80 (both Overweight)[cite: 5].
In February 2026 LYB cut its quarterly dividend to $0.69 — a reduction of $0.68, roughly half[cite: 5]. The current $2.76 annual rate yields ~4.7%, and on August 14 the board declared the next $0.69 payment for August 31, ex-dividend August 24 — inside this week's window[cite: 5]. Income readers should size that yield knowing the payout was already halved once this year[cite: 5].
No earnings next week — Q2 reported July 31[cite: 5]. The dated event is the August 24 ex-dividend date for the $0.69 payment (payable Aug 31)[cite: 5].
Benefits from easing rate pressure the usual way — leveraged industrial cyclicals prefer a Fed that has stopped tightening — but its real drivers are petrochemical spreads, natural gas costs and the Middle East[cite: 5]. At ~7× forward earnings with a 4.7% yield the value case is real; the question is whether those forward earnings are a peak[cite: 5].
Best frequency on the list, a genuine record quarter, a ~7× forward multiple and an ex-dividend date inside the window[cite: 5]. The counterweight is unavoidable: those earnings are war-inflated and above normalized levels, the dividend was already halved in February, and targets run $48 to $80[cite: 5]. A cyclical value setup, sized for a cycle that may be peaking[cite: 5].
The binary catalyst
Start with the number that matters most, because it is the whole story[cite: 5]. DBVT's 1.95 profit factor is the lowest figure this newsletter has ever put in front of you — below WATT's 3.39 and CRM's 2.37[cite: 5].
In plain English: across this window's history, winning periods have outweighed losers by less than two to one[cite: 5]. The 81.82% frequency and 72.73% win rate say the pattern shows up often; the profit factor says that when it fails, it gives back nearly everything the winners earned[cite: 5]. This is a low-margin-of-error setup, and position sizing is not optional.[cite: 5]
DBV is a clinical-stage French biopharma developing Viaskin, a skin patch delivering epicutaneous immunotherapy to train patients to tolerate food allergies — principally peanut allergy in children[cite: 5]. The FDA previously granted Breakthrough Therapy Designation, the pivotal Phase 3 VITESSE trial hit its endpoint, the stock is up ~85% over twelve months, and it joined the Euronext Tech Leaders Index in June[cite: 5].
DBV expects to submit its BLA for the Viaskin Peanut Patch in children aged 4–7 during Q3 2026 — which is to say, now[cite: 5]. Pre-filing discussions with the FDA focused on organizing existing data for review efficiency, with no additional data requested[cite: 5]. Submission triggers a ~10-month review and a potential 2027 launch[cite: 5]. Six analysts cover it with a Buy consensus and a ~$40.73 average target; Cantor, Guggenheim and Citizens have all reiterated Buys[cite: 5].
DBVT is pre-revenue[cite: 5]. It lost $98.0M in the first half of 2026 alone, with $174.9M of cash funding operations only into Q3 2027 — and it has already raised up to $306.9M via a private placement with warrants, diluting holders[cite: 5]. The BLA has slipped once already, from Q2 into Q3[cite: 5]. And the commercial precedent is sobering: competing peanut therapy Palforzia saw notably sluggish uptake[cite: 5]. A binary regulatory bet on a ~$950M company, not a diversified business[cite: 5].
No earnings next week — H1 results are out[cite: 5]. The live event is the Q3 2026 BLA submission, which could land at any point in the window[cite: 5].
Almost entirely detached from the Fed — no CPI print moves a peanut-allergy patch approval[cite: 5]. But small, unprofitable, cash-burning biotechs are among the most sentiment-sensitive assets there are, so easing rate pressure and improved risk appetite are a genuine background tailwind[cite: 5]. The swing factor is the FDA, full stop[cite: 5].
A high-frequency window into a specific, near-term catalyst — a Q3 BLA with no outstanding FDA data requests, Breakthrough designation behind it, and targets more than double the price[cite: 5]. But the 1.95 profit factor is the weakest we have published, on a pre-revenue, cash-burning, dilutive company[cite: 5]. Treat this as a speculation sized to be wrong[cite: 5].
The quality compounder
GWRE brings the highest annualized return on the list at 101.72% — the only triple-digit figure here — and the best win rate at 76.92%, with an 85.71% frequency and 5.95 profit factor[cite: 5]. On raw quality of profile, the strongest of the three[cite: 5].
Regular readers will recognize it: we featured Guidewire two weeks ago in the August 3 issue, when enterprise software was being punished and the stock sat near $153[cite: 5]. It is the dominant platform for the global P&C insurance industry — PolicyCenter, ClaimCenter and BillingCenter run insurers' core operations — deep into a high-margin cloud transition, with 27% revenue growth, ARR up 19% to $1.15B, raised guidance and a $500M buyback[cite: 5].
The stock has already climbed to roughly $175 — up about 14% from where we flagged it[cite: 5]. The thesis worked, and quickly[cite: 5]. The setup is still constructive: Piper Sandler initiated at Overweight on August 10, Stifel reiterated Buy on August 11, and the average target sits near $201 against a $137–$258 range[cite: 5]. But the easy discount is gone — you are buying this after a 14% move, not before it.[cite: 5]
Fiscal Q4 expected around September 3, 2026 (est., after close) — after this week's window opens, not during it[cite: 5]. Watch ARR growth and FY27 guidance[cite: 5].
The most valuation-sensitive name here — a premium multiple on a long-duration grower — which is precisely why the softer CPI and receding September hike help it most of the three[cite: 5]. The franchise is genuinely sticky: insurers don't rip out core policy and claims systems easily[cite: 5]. The risks are that rich multiple and the unresolved AI-versus-seat-based-software debate[cite: 5].
Best annualized return and win rate here, attached to the stickiest business — and the softer print helps its premium multiple more than anything else on the list[cite: 5]. The honest caveat: up ~14% since we featured it August 3, so the entry is materially worse[cite: 5]. Still below a ~$201 average target, with fresh Overweight and Buy coverage[cite: 5].
The three setups, side by side
| Ticker | Frequency | Profit Factor | Ann. Return | Annual Win % | Catalyst |
|---|---|---|---|---|---|
| LYBLyondellBasell | 87.5% | 7.13 | 68.5% | 73.33% | Ex-dividend Aug 24 |
| DBVTDBV Technologies | 81.82% | 1.95 | 73.34% | 72.73% | Q3 BLA submission |
| GWREGuidewire Software | 85.71% | 5.95 | 101.72% | 76.92% | Earnings ~Sep 3 |
The Big Picture
Three names, three genuinely different engines — chosen so the week does not depend on a single thesis being right[cite: 5].
Notice how differently the same macro reads across them[cite: 5]. The receding September hike is a direct tailwind for GWRE's premium multiple, a mild positive for a leveraged cyclical like LYB, and largely irrelevant to DBVT, whose fate rests with the FDA rather than the Fed[cite: 5]. Meanwhile the softening labor market that helped cool those hike odds is itself a warning for industrial demand — which is LYB's risk, not Guidewire's[cite: 5]. Spreading exposure across a cycle trade, a catalyst trade and a quality compounder is how you keep one wrong assumption from deciding the whole week[cite: 5].
The goal is never to predict the week perfectly[cite: 5]. Seasonality gives you the roadmap; the data and catalyst calendars give you the events; the Fed backdrop tells you which risks to size carefully[cite: 5]. From there: watch the price action, respect your stops, and refuse to let emotion decide[cite: 5].
Sign Up to View Full Trade DetailsSuper Seasonal Trade Desk
